Solid tumors after chemotherapy or surgery for testicular nonseminoma: A population-based study

Journal of Clinical Oncology

Volumn 31, Issue 30, 2013, Pages 3807-3814

  Fung, Chunkit ^a   Fossa, Sophie D ^b   Milano, Michael T ^a   Oldenburg, Jan ^b   Travis, Lois B ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN;

ADULT; ARTICLE; BLADDER CANCER; BRAIN CANCER; BRONCHUS CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURGERY; COHORT ANALYSIS; COLON CANCER; ESOPHAGUS CANCER; FOLLOW UP; HEART CANCER; HISTOPATHOLOGY; HUMAN; KAPOSI SARCOMA; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; NERVOUS SYSTEM CANCER; PANCREAS CANCER; PHARYNX CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; SECOND CANCER; SOFT TISSUE CANCER; SOFT TISSUE TUMOR; SOLID MALIGNANT NEOPLASM; STOMACH CANCER; TESTIS NONSEMINOMA CANCER; THYROID CANCER; THYROID PAPILLARY CARCINOMA; URINARY TRACT CANCER; ADJUVANT CHEMOTHERAPY; CANCER REGISTRY; INCIDENCE; KIDNEY NEOPLASMS; MORTALITY; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, SECOND PRIMARY; RISK ASSESSMENT; RISK FACTOR; SOFT TISSUE NEOPLASMS; TESTICULAR NEOPLASMS; THYROID NEOPLASMS; UNITED STATES;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, SECOND PRIMARY; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; SOFT TISSUE NEOPLASMS; TESTICULAR NEOPLASMS; THYROID NEOPLASMS; UNITED STATES;

EID: 84891522512     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.3409     Document Type: Article

References (61)

1. Siegel R, DeSantis C, Virgo K, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220-241, 2012
2. Huyghe E, Matsuda T, Thonneau P: Increasing incidence of testicular cancer worldwide: A review. J Urol 170:5-11, 2003
3. Verdecchia A, Francisci S, Brenner H, et al: Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8:784-796, 2007
4. Einhorn LH, Donohue J: Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293-298, 1977
5. Bachaud JM, Berthier F, Soulié M, et al: Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma. Radiother Oncol 50:191-197, 1999
6. Fosså SD, Langmark F, Aass N, et al: Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. Br J Cancer 61:639-643, 1990
7. Hemminki K, Liu H, Sundquist J: Second cancers after testicular cancer diagnosed after 1980 in Sweden. Ann Oncol 21:1546-1551, 2010
8. Richiardi L, Scélo G, Boffetta P, et al: Second malignancies among survivors of germ-cell testicular cancer: A pooled analysis between 13 cancer registries. Int J Cancer 120:623-631, 2007
9. Travis LB, Curtis RE, Storm H, et al: Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89: 1429-1439, 1997
10. Travis LB, Fosså SD, Schonfeld SJ, et al: Second cancers among 40,576 testicular cancer patients: Focus on long-term survivors. J Natl Cancer Inst 97:1354-1365, 2005
11. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al: Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370-4378, 2007
12. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, et al: Second cancer risk following testicular cancer: A follow-up study of 1,909 patients. J Clin Oncol 11:415-424, 1993
13. Wanderås EH, Fosså SD, Tretli S: Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer 33:253-262, 1997
14. Travis LB, Ng AK, Allan JM, et al: Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst 104:357-370, 2012
15. van den Belt-Dusebout AW, Aleman BM, Besseling G, et al: Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 75:1420-1429, 2009
16. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337:242-253, 1997
17. Greene MH: Is cisplatin a human carcinogen? J Natl Cancer Inst 84:306-312, 1992
18. Travis LB, Holowaty EJ, Bergfeldt K, et al: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 340:351-357, 1999
19. Travis LB, Andersson M, Gospodarowicz M, et al: Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92:1165-1171, 2000
20. Hawkins MM, Wilson LM, Burton HS, et al: Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 88:270-278, 1996
21. Travis LB, Curtis RE, Glimelius B, et al: Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 87:524-530, 1995
22. Travis LB, Gospodarowicz M, Curtis RE, et al: Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 94: 182-192, 2002
23. Tucker MA, D'Angio GJ, Boice JD Jr, et al: Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 317:588-593, 1987
24. Veiga LH, Bhatti P, Ronckers CM, et al: Chemotherapy and thyroid cancer risk: A report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 21:92-101, 2012
25. Bokemeyer C, Schmoll HJ: Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11:1703-1709, 1993
26. Osswald M, Harlan LC, Penson D, et al: Treatment of a population based sample of men diagnosed with testicular cancer in the United States. Urol Oncol 27:604-610, 2009
27. Daugaard G, Petersen PM, Rørth M: Surveillance in stage I testicular cancer. APMIS 111:76-83, 2003
28. Read G, Stenning SP, Cullen MH, et al: Medical Research Council prospective study of surveillance for stage I testicular teratoma: Medical Research Council Testicular Tumors Working Party. J Clin Oncol 10:1762-1768, 1992
29. Chevreau C, Mazerolles C, Soulié M, et al: Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 46:209-214, 2004
30. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
31. Kondagunta GV, Bacik J, Bajorin D, et al: Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 23:9290-9294, 2005
32. Hinton S, Catalano PJ, Einhorn LH, et al: Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: Final analysis of an intergroup trial. Cancer 97:1869-1875, 2003
33. Nichols CR, Catalano PJ, Crawford ED, et al: Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 16:1287-1293, 1998
34. Kondagunta GV, Bacik J, Donadio A, et al: Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 23:6549-6555, 2005
35. Oechsle K, Bokemeyer C: Treatment of brain metastases from germ cell tumors. Hematol Oncol Clin North Am 25:605-613, 2011
36. Dores GM, Metayer C, Curtis RE, et al: Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years. J Clin Oncol 20:3484-3494, 2002
37. Curtis R, Freedman DM, Ron E, et al (eds): New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD, National Cancer Institute, 2006
38. Breslow NE, Day NE: Statistical methods in cancer research: Volume II-The design and analysis of cohort studies. IARC Sci Publ 82:1-406, 1987
39. Travis LB, Beard C, Allan JM, et al: Testicular cancer survivorship: Research strategies and recommendations. J Natl Cancer Inst 102:1114-1130, 2010
40. Brouwers EE, Huitema AD, Beijnen JH, et al: Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol 8:7, 2008
41. Tothill P, Klys HS, Matheson LM, et al: The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur J Cancer 28A: 1358-1361, 1992
42. Poirier MC, Reed E, Litterst CL, et al: Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 52:149-153, 1992
43. Gerl A, Schierl R: Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer. Acta Oncol 39:519-522, 2000
44. Israel GM, Silverman SG: The incidental renal mass. Radiol Clin North Am 49:369-383, 2011
45. Jayson M, Sanders H: Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51:203-205, 1998
46. Wilson CL, Ness KK, Neglia JP, et al: Renal carcinoma after childhood cancer: A report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 105:504-508, 2013
47. Pal T, Vogl FD, Chappuis PO, et al: Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: A hospital-based study. J Clin Endocrinol Metab 86:5307-5312, 2001
48. Kim HJ, Kim NK, Choi JH, et al: Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clin Endocrinol (Oxf) 78:134-140, 2013
49. Haugnes HS, Aass N, Fosså SD, et al: Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 18:241-248, 2007
50. Motzer RJ, Amsterdam A, Prieto V, et al: Teratoma with malignant transformation: Diverse malignant histologies arising in men with germ cell tumors. J Urol 159:133-138, 1998
51. Jenkinson HC, Winter DL, Marsden HB, et al: A study of soft tissue sarcomas after childhood cancer in Britain. Br J Cancer 97:695-699, 2007
52. Shinn EH, Swartz RJ, Thornton BB, et al: Testis cancer survivors' health behaviors: Comparison with age-matched relative and demographically matched population controls. J Clin Oncol 28:2274-2279, 2010
53. Centers for Disease Control and Prevention: Current cigarette smoking prevalence among working adults-United States, 2004-2010. MMWR Morb Mortal Wkly Rep 60:1305-1309, 2011
54. Swerdlow AJ, Schoemaker MJ, Allerton R, et al: Lung cancer after Hodgkin's disease: A nested case-control study of the relation to treatment. J Clin Oncol 19:1610-1618, 2001
55. Berrington de González A, Mahesh M, Kim KP, et al: Projected cancer risks from computed tomographic scans performed in the United States in 2007. Arch Intern Med 169:2071-2077, 2009
56. Oldenburg J, Martin JM, Fosså SD: Late relapses of germ cell malignancies: Incidence, management, and prognosis. J Clin Oncol 24:5503-5511, 2006
57. Gilligan T: Are we scanning testis cancer patients too often? Cancer 117:4108-4111, 2011
58. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
59. Travis LB: Therapy-associated solid tumors. Acta Oncol 41:323-333, 2002
60. Travis LB, Rabkin CS, Brown LM, et al: Cancer survivorship: Genetic susceptibility and second primary cancers-Research strategies and recommendations. J Natl Cancer Inst 98:15-25, 2006
61. Wood ME, Vogel V, Ng A, et al: Second malignant neoplasms: Assessment and strategies for risk reduction. J Clin Oncol 30:3734-3745, 2012